Your search returned 6 results.

Results
	1.	Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis. [electronic resource] by Palaparthy, Rameshraja Rehman, Muhammad I von Richter, Oliver Yin, Donghua Producer: 20200420 In: Expert opinion on biological therapy vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. [electronic resource] by May, Ekkehard Dorris, Martha L Satumtira, Nimman Iqbal, Imran Rehman, Muhammad I Lightfoot, Ellis Taurog, Joel D Producer: 20030304 In: Journal of immunology (Baltimore, Md. : 1950) vol. 170 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. [electronic resource] by McClellan, Joseph E Conlon, Hugh D Bolt, Michael W Kalfayan, Vatche Palaparthy, Rameshraja Rehman, Muhammad I Kirchhoff, Carol F Publication details: Therapeutic advances in gastroenterology 2019 In: Therapeutic advances in gastroenterology vol. 12 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01). [electronic resource] by Palaparthy, Ramesh Udata, Chandrasekhar Hua, Steven Y Yin, Donghua Cai, Chun-Hua Salts, Stephanie Rehman, Muhammad I McClellan, Joseph Meng, Xu Producer: 20190221 In: Expert review of clinical immunology vol. 14 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial. [electronic resource] by Cohen, Stanley B Radominski, Sebastiao C Kameda, Hideto Kivitz, Alan J Tee, Michael Cronenberger, Carol Zhang, Min Hackley, Sarah Rehman, Muhammad I von Richter, Oliver Alten, Rieke Producer: 20210127 In: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 34 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. [electronic resource] by Cohen, Stanley B Alten, Rieke Kameda, Hideto Hala, Tomas Radominski, Sebastiao C Rehman, Muhammad I Palaparthy, Ramesh Schumacher, Karl Schmitt, Susanne Hua, Steven Y Ianos, Claudia Sewell, K Lea Producer: 20190514 In: Arthritis research & therapy vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)